Alivus Life Sciences Ltd Financials
Company Logo

Alivus Life Sciences Ltd Financial Statement

Alivus Life Sciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue610.83
Operating Expense429.54
Net Profit121.54
Net Profit Margin19.90
Earning Per Share9.91
EBIDTA178.79
Effective Tax Rate21.48

Alivus Life Sciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual2,386.88
Operating Expenses Annual1,704.30
Operating Profit Annual717.15
Interest Annual2.41
Depreciation60.61
Net Profit Annual485.63
Tax Annual168.50

Alivus Life Sciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning301.41
Cash Flow from Operations391.52
Cash Flow from Investing-615.65
Cash Flow from Financing-6.23
Cash Flow at the End71.06

Alivus Life Sciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)30.05
PBIT Margin (%)27.51
PBT Margin (%)16.10
Net PROFIT Margin (%)20.35
Return On Networth / Equity (%)18.86
Return On Networth /Employed (%)24.97
Return On Assets (%)18.51
Total Debt / Equity (X)0.01
Asset Turnover Ratio (%)0.91

Alivus Life Sciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual962.61
Total Current Assets Annual2,335.16
Non Current Assets Annual1,076.30
Total Shareholders Funds Annual2,817.37
Total Assets Annual3,411.45

Alivus Life Sciences Ltd Earning Calls

No Data Availabe

FAQS on Alivus Life Sciences Ltd Financials

As of Aug 30, 2025, Alivus Life Sciences Ltd has a market capitalization of 13,229.10 Cr. Value Research classifies it as a Large-Cap company.

Yes, Alivus Life Sciences Ltd is with a debt-to-equity ratio of 0.02.

In FY 2024 , Alivus Life Sciences Ltd recorded a total revenue of approximately 2,386.88 Cr marking a significant milestone in the company's financial performance.

Alivus Life Sciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.5% and 0.0% annually, respectively..

Alivus Life Sciences Ltd's current PE ratio is 27.24.

Alivus Life Sciences Ltd's ROCE averaged 26.3% from the FY ending March 2023 to 2025, with a median of 26.9%. It peaked at 29.2% in March 2023, reflecting strong capital efficiency over the period..

Alivus Life Sciences Ltd's latest EBIT is Rs. 656.54 Cr, surpassing the average EBIT of Rs. 639.51 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions